Cannabigerol -The Emerging Cannabinoid

Unique Pharmacological Properties

CBG’s pharmacological profile is distinct, with interactions at adrenergic and serotonin receptors, which are not typical for other cannabinoids. It also acts as a dual PPARa/g agonist, influencing metabolic processes and inflammation.

Current Clinical Trials

CBG is currently being studied for its anti-inflammatory and neuroprotective effects. One trial is investigating CBG’s potential in treating inflammatory bowel disease, with promising preliminary results. Another study is exploring CBG’s role in managing glaucoma, a condition characterized by increased intraocular pressure.

Future Healthcare Potential

The future of CBG in healthcare is promising, with potential applications in treating metabolic disorders, neurodegenerative diseases, and bacterial infections. Its unique pharmacological properties offer new therapeutic avenues that are not accessible with other cannabinoids. As research continues, CBG could emerge as a valuable tool in the cannabinoid arsenal, providing benefits without the psychoactive effects of THC.

CBG Molecule

Process Validation and Stability Testing of Cannabigerol

Process Validation and Stability Testing of Cannabigerol (CBG) Isolate under ICH Q7 Validating a novel cannabinoid such as cannabigerol (CBG) isolate as an Active Pharmaceutical Ingredient (API) under […]

Cannabigerol (CBG): Therapeutic Promise and Limitations

CBG is attracting significant interest due to its unique pharmacological profile and therapeutic potential. Notably, CBG interacts only weakly with canonical cannabinoid receptors (CB₁ and CB₂) – it is […]

CBG/CBD Oil for Chemotherapy‑Induced Peripheral Neuropathy

Phase I Trial of CBG/CBD Oil for Chemotherapy‑Induced Peripheral Neuropathy Introduction: The Burden of CIPN Chemotherapy-induced peripheral neuropathy (CIPN) is a common and debilitating adverse effect […]

The Distrio Network

The Distrio Network is a content hub for procurement, quality assurance, and technical professionals in the global cannabinoid supply chain. Built using DistrioGPT, with cannabinoid-specific websites delivering blogs, guest stories, and deep dives on the latest research, cannabis-focused professionals will find in-depth and engaging content about these molecules and their markets.

CBD: The Therapeutic Non-Psychoactive Cannabinoid

Cannabidiol (CBD) is a non-psychoactive cannabinoid that has gained popularity for its potential therapeutic benefits. Unlike THC, CBD does not produce a high, making it appealing for medical use. It interacts with various receptors in the body, notably enhancing the activity of serotonin 1A receptors, which contributes to its anxiolytic (anxiety-reducing) effects. CBD’s low oral bioavailability (~6%) is due to its extensive first-pass metabolis]. Clinically, CBD has been shown to reduce seizure frequency in epilepsy, particularly in conditions like Dravet syndrome. Ongoing research continues to explore its efficacy in treating anxiety disorders, chronic pain, and inflammation.

CBG: The Emerging Cannabinoid

Cannabigerol (CBG) is a lesser-known, non-psychoactive cannabinoid that is gaining attention for its potential health benefits. CBG is unique because it acts as a precursor to other cannabinoids, including THC and CBD. This means that during the cannabis plant’s growth, CBG is converted into these more prevalent cannabinoids. CBG is being studied for its anti-inflammatory and neuroprotective properties, with early research suggesting it may be beneficial for conditions like inflammatory bowel disease and glaucoma. Although clinical trials are limited, the ongoing research into CBG’s pharmacological effects is promising, highlighting its potential as a therapeutic agent without psychoactive effects.

THC: The Psychoactive Cannabinoid

Tetrahydrocannabinol (THC) is the most well-known cannabinoid, primarily responsible for the psychoactive effects of cannabis. When consumed, THC is rapidly absorbed into the bloodstream, especially when inhaled, with a bioavailability ranging from 10-35%. This means that a significant portion of THC enters the bloodstream and reaches the brain, where it binds to CB1 receptors, producing the characteristic “high.” A unique aspect of THC is its conversion into 11-hydroxy-THC, a metabolite that enhances its psychoactive effects, through the liver. Beyond its recreational use, THC is being studied in clinical trials for its potential to alleviate chronic pain and spasticity associated with multiple sclerosis. These trials aim to harness THC’s analgesic properties while managing its psychoactive effects.